Search
BIO 2026: After presenting updated data at both ASH and EHA, Paris based Enterome is hoping to start a phase 3 for its multi-target peptide immunotherapy in follicular lymphoma
Co-Founder and CEO Pierre Belichard describes the program, which is made up of four synthetic microbial-derived peptides designed to mimic CD20, CD22, CD37 and CD268, and UCP2, and walks us through the recent medical meeting presentations. Plus, Enterome's efforts to get investors or a strategic partner to support the phase 3. Coverage brought to you by
4 days ago
Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system
CEO Pierre Belichard describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in...
Sep 5, 2024
.png){kind=logo}